Bioorganic & Medicinal Chemistry Letters 17 (2007) 1908≠1911

Design of LFA-1 antagonists based on a 2,3-dihydro-1Hpyrrolizin-5(7aH)-one scaffold
Dharmpal S. Dodd,a,* Steven Sheriff,a ChiehYing J. Chang,a Dawn K. Stetsko,a Linda M. Phillips,a Yingru Zhang,a Michele Launay,b Dominique Potin,b Wayne Vaccaro,a Michael A. Poss,a Murray McKinnon,a Joel C. Barrish,a Suzanne J. Sucharda and T. G. Murali Dhara
a

Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543-4000, USA b Cerep, 19 avenue du Quebec, 91951 Courtaboeuf cedex, France
Received 15 December 2006; accepted 10 January 2007 Available online 24 January 2007

Abstract--A new class of lymphocyte function-associated antigen-1 (LFA-1) antagonists is described. Elaboration of the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold resulted in the synthesis of potent inhibitors of the LFA-1/ICAM-1 interaction. Along with the in vitro activity, we present the X-ray crystal structure of the complex of compound 9b, in a novel binding mode to the I-domain of LFA-1. ” 2007 Elsevier Ltd. All rights reserved.

The cell adhesion molecule LFA-1 (lymphocyte functionassociated antigen-1), also known as CD11a/CD18, is known to play a crucial role in many immunological functions including antigen presentation, leukocyte trafficking, B- and T-cell activation. LFA-1 belongs to the b2 integrin family and is found on all leukocytes.1 The ligands for LFA-1, the ICAMs 1≠3 (intercellular adhesion molecules), are expressed on both leukocytes and the endothelium. In particular, the interaction of LFA1 with ICAM-1 results in leukocyte adhesion to the endothelium and facilitates their extravasation to tissue sites.2,3 The LFA-1/ICAM interaction has been proposed to be an attractive therapeutic target in the treatment of several inflammatory disorders such as psoriasis and transplant rejection.4,5 The recent approval of efalizumab (Raptiva“), a fully humanized anti-LFA-1 antibody for the treatment of moderate to severe psoriasis, provides excellent validation of the target.6 In the search for small molecules that would interfere with the LFA-1/ICAM-1 interaction, we and others

have disclosed several diverse chemical series of compounds.7,8 Some representative structures are shown in Figure 1. NMR and X-ray co-crystallographic studies have established that many of these inhibitors bind to the IDAS site (I-domain allosteric site) of the I-domain located on the CD11a unit.7≠9 The X-ray structure of our clinical candidate BMS-5871017a in complex with the I-domain of LFA-1 shows the following: (i) the

S Cl O N Cl N HO O Cl O

Br

O BMS-587101

N Me

CN Cl

Me N O Me BIRT-377 NO2 N N O A-286982

N

Br
Me Me S

Cl

O N N O (1)

Ac

Keywords: LFA-1 antagonists; 2,3-Dihydro-1H-pyrrolizin-5-(7aH)-one; LFA-1/ICAM interaction. * Corresponding author. Tel.: +1 609 252 5273; e-mail: dharmpal. dodd@bms.com 0960-894X/$ - see front matter ” 2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2007.01.036

Cl

Figure 1. Representative LFA-1 antagonists reported in the literature.

D. S. Dodd et al. / Bioorg. Med. Chem. Lett. 17 (2007) 1908≠1911

1909

p-cyanophenyl aromatic ring forms a favorable edge-toface p≠p interaction with the 3,5-dichlorophenyl ring; (ii) the urea carbonyl is hydrogen bonded to the amino acid residues Lys-NH2 305, Lys-NH2 287, and GluCOOH 284 via a water molecule. Unlike the urea carbonyl, the amide carbonyl does not appear to make any discernible contacts with the protein. As a continuation of our work7b on the modification of the reported bicyclic[5.5]hydantoin core 1,8c we herein describe exploration of the 2,3-dihydro-1H-pyrrolizin5(7aH)-one core 2 as a suitable surrogate in the design of LFA-1 inhibitors. Replacement of the N-6 nitrogen of the urea with a carbon atom and introduction of unsaturation in ring A provide structural rigidity similar to the bicyclic[5.5]hydantoin class of compounds, while retaining the all important carbonyl (C-5) as well as the 3,5-dichlorophenyl and benzyl groups necessary for high affinity. In addition, the pyrrolizinone core allows for elaboration at the C-7 position, thus providing an understanding of the SAR at this position (Fig. 2). The synthesis of the 2,3-dihydro-1H-pyrrolizin-5(7aH)ones is outlined in Schemes 1 and 2. In our initial approach (Scheme 1), homochiral N-boc-L -proline methyl ester (3) was elaborated to give 7-hydroxy pyrrolizin-5one 6 in reasonable overall yield. Compound 6 served as the key intermediate for the synthesis of compounds 7, 9, and 10. Unfortunately, C≠C coupling of the O-triflate 8 was not general and failed with copper mediated alkyl/aryl Grignards or lithium reagents. This necessitated the development of a more general approach utilizing 3 as the starting material (Scheme 2). The new sequence (Scheme 2) was used to prepare compounds 15≠18. Inhibition of the LFA-1/ICAM binding interaction using the HeLa/HSB assay7b for a limited number of racemic 2,3-dihydro-1H-pyrrolizin-5(7aH)-ones is shown in Table 1. The data clearly suggest that the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one core is an excellent surrogate for the bicyclic[5.5]hydantoin system. The enol 6 was essentially inactive, as was the bulky 3-pyrazolyl derivative 17. Compound 7 with a H-bond accepting methoxy group at C-7 displayed sub-micromolar potency in the HeLa/HSB assay. The potency increase was significantly more pronounced for compounds 9 (R = CN) and 18 (R = Et), which displayed IC50s of 40 and 52 nM, respectively, in the HeLa/HSB binding assay. The C-7 SAR for the cyano analog (9) and the ethyl analog (18) was intriguing considering the hydrophilic and hydrophobic nature of these two substituents. These data suggested that either (i) the C-7 position of
Br
Cl O
7 7a 1

NC

NC

MeO2C
Boc N

a 3

MeO2C
Boc N

b,c 4
CN Cl Cl Cl

O MeO N O 5 CN

d

Cl

OH N O 6

f

OTf N O8

Cl

Cl

e
CN Cl MeO N Cl O Cl R

g or h
CN

Cl

7

N O 9: R= CN 10: R=Me

Scheme 1. Reagents and conditions: (a) i--LiHMDS, THF, ¿78 ∞C, ii--4-cyanobenzyl chloride, THF, 30%; (b) 4 N HCl-dioxane; (c) (3,5dichlorophenyl)acetic acid, EDCI, DIPEA, DMF, 95%; (d) LiHMDS, THF, 90%; (e) (MeO)3PO, K2CO3, reflux, 10 h, 30%; (f) Tf2O, DIPEA, DCM, ¿10 ∞C, 60%; (g) Pd(PPh3)4, Zn(CN)2, DIPEA, DMF, 195 ∞C, 10 min microwave, 75%; (h) (CH3)2(CN)CuLi, THF, ¿78 ∞C, 15%.

Br MeO2C Boc N 3 a MeO2C Boc Br c O R N Boc 13 Br f Cl R N Cl O g Cl d,e Cl Cl R N O O R N O 14 N 11 b O O N N Boc 12

Br

Br

CN

Cl 15: R=Et 16: R=c-Pr 17: R=3-Pyrazolyl

18: R=Et

X
Cl R
7 7a 1 5

Scheme 2. Reagents and conditions: (a) i--LiHMDS, THF, ¿78 ∞C, ii--4-bromobenzyl bromide, THF, 85%; (b) LiN(OMe)Me, THF, ¿10 ∞C; (c) RMgBr or lithium pyrazol-1-id-3-yllithium, THF rt; (d) 4 N HCl-dioxane; (e) (3,5-dichlorophenyl)acetic acid, EDCI, DIPEA, DMF, 90≠95%; (f) 5% KOH in MeOH, reflux (60≠80%); (g) Pd(PPh3)4, Zn(CN)2, DMF, 200 ∞C, 20 min microwave (80%).

NA Cl O 1
5

N

B

A

N

B

Cl

O 2

Figure 2. Bicyclic[5.5]hydantoin core (1) and 2,3-dihydro-1H-pyrrolizin-5(7aH)-one core (2).

the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one core tolerates a variety of lipophilic and hydrophobic substituents or (ii) the binding mode for these compounds with the Idomain of LFA-1 may be different. To further understand this discrepancy in the SAR, the cyano analog (9) was co-crystallized with the I-domain of LFA-1.

1910

D. S. Dodd et al. / Bioorg. Med. Chem. Lett. 17 (2007) 1908≠1911

Table 1. In vitro activity of racemic 2,3-dihydro-1H-pyrrolizin5(7aH)-ones Compound BIRT-377 6 7 9 10 15 16 17 18
a b

Cl

O N
R

Cl

O N
S

R

X

HeLa/HSB bindinga (IC50 or % inhibition) 26 nMb 27% at 1 lM 430 nM 40 nM 660 nM 106 nM 200 nM 30% at 10 lM 52 nM

Cl N CN
9a: HeLa/HSB binding IC 50=1.4 M

Cl N CN
9b: HeLa/HSB binding IC 50=15 nM

OH OCH3 CN CH3 Et Cyclopropyl 3-Pyrazolyl Et

CN CN CN CN Br Br Br CN

Figure 4. Absolute stereochemistry of 9a and 9b.

Values are averages of at least two determinations. Kd value in an LFA-1/ICAM-1 binding assay as reported in the literature.9

group at C-6 is not positioned as deeply in the hydrophobic pocket between a-helices 1 and 7 and b-strands 1, 3, and 4 as was found for BMS-587101. Compound 9 was separated into its individual enantiomers 9a and 9b employing a Chiralpak AD column and the compounds tested for LFA-1/ICAM binding inhibition in the HeLa/HSB assay. As expected, there was a marked difference in the inhibition potential of these enantiomers. The faster eluting enantiomer, 9a, was much less active and displayed an IC50 of 1.4 lM, while the slower eluting enantiomer, 9b, had an IC50 of 15 nM (Fig. 4). The absolute stereochemistry for 9b was established as S at the 7a position employing vibrational circular dichroism (VCD) spectroscopic analysis.12 This result is consistent with the absolute stereochemistry of the compound in the X-ray co-crystal structure (vide supra). The accommodation of 9b in a binding mode opposite to that of the hydantoin class of LFA-1 antagonists is evidence of the flexibility of the I-domain of the LFA1 protein. Since only 9 was subjected to X-ray crystallographic analysis, we cannot be certain that this opposite `flipped' binding mode is an inherent property of the 2,3dihydro-1H-pyrrolizin-5(7aH)-one core or just unique to the C-7 cyano substituted compounds in this series. Racemic 18, containing an ethyl group at C-7, was equipotent to 9 (IC50 = 52 nM) in the HeLa/HSB binding assay. The lack of hydrogen-bonding ability of the ethyl group does not preclude the possibility that this compound may be binding in the `traditional' mode similar to the hydantoin class of LFA-1 antagonists. In conclusion, we have designed a novel class of LFA-1/ ICAM antagonists based on the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold. X-ray crystal structural analysis of our most active compound 9b revealed a `flipped' binding mode to the I-domain of the LFA-1 protein. The stereochemistry of 9b was found to be 7a(S), which is opposite to that found in the hydantoin class of LFA1 antagonists. Acknowledgments

When racemic 9 was co-crystallized with the I-domain of LFA-1, a single enantiomer (S) was found bound to the I-domain. Figure 3 shows the X-ray co-crystal structure ∞ of this enantiomer (designated 9b) determined at 1.75 A resolution.10 The X-ray co-crystal structure revealed a novel binding mode for compound 9b when compared to the hydantoin class of LFA-1 antagonists such as BMS-587101 and BIRT-377, where the absolute stereochemistry at the equivalent of the C-7a center is (R)9. This `flipped' binding mode for compound 9b is a direct result of the vinyl cyano group at C-7a forming a hydrogen bonding network through a water molecule to LysNH2 287 and Lys-NH2 305 and Glu-COOH 284, unlike BMS-587101 where the urea carbonyl, which corresponds to the C-5 carbonyl of 9b, forms the same hydrogen bonding network. In addition, the Tyr-OH 166, which is too far from the C-2 carbonyl of BMS587101 to form a H-bond, has now moved in the direction of the carbonyl of 9b, and is capable of forming a direct H-bond. Interestingly, the 3,5-dichlorophenyl

Figure 3. X-ray structure of 9b complexed with the I-domain of LFA-1. Also shown is the initial electron density (magenta: 2Fo-Fc 1) prior to fitting compound 9b. The water molecule is shown as a red sphere and hydrogen bonds are shown as small cyan spheres. Figure created using PyMol.11

The authors thank Deepa Calambur for providing the LFA-1 protein for X-ray crystallographic studies and Jack Z. Gougoutas for helpful discussions regarding the VCD spectra for compound 9b.

D. S. Dodd et al. / Bioorg. Med. Chem. Lett. 17 (2007) 1908≠1911

1911

References and notes
1. Harris, E. S.; McIntyre, T. M.; Prescott, S. M.; Zimmerman, G. A. J. Biol. Chem 2000, 275, 23409. 2. Hogg, N.; Henderson, R.; Leitinger, B.; McDowall, A.; Porter, J.; Stanley, P. Immunol. Rev. 2002, 186, 164. 3. Shimaoka, M.; Xiao, T.; Liu, J.-H.; Yang, Y.; Dong, Y.; Jun, C.-D.; McCormack, A.; Zhang, R.; Joachimiak, A.; Takagi, J.; Wanh, J.-H.; Springer, T. A. Cell 2003, 112, 99. 4. Liu, G. Drugs Future 2001, 26, 767. 5. Dedrick, R. L.; Walicke, P.; Garovoy, M. Transpl. Immunol. 2002, 9, 181. 6. Cather, J. C.; Cather, J. C.; Menter, A. Expert Opin. Biol. Ther. 2003, 3, 361. 7. (a) Potin, D.; Launay, M.; Monatlik, F.; Malabre, P.; Fabreguettes, M.; Fouquet, A.; Maillet, M.; Nicolai, E.; Dorgeret, L.; Chevallier, F.; Besse, D.; Dufort, M.; Caussade, F.; Ahmad, S. Z.; Stetsko, D. S.; Skala, S.; Davis, P. M.; Balimane, P.; Patel, K.; Yang, Z.; Marathe, P.; Postelneck, J.; Townsend, R. M.; Goldfarb, V.; Sheriff, S.; Einspahr, H.; Kish, K.; Malley, M. F.; DiMarco, J. D.; Gougoutas, J. Z.; Kadiyala, P.; Cheney, D. L.; Tejwani, R. W.; Murphy, D. K.; Mcintyre, K. W.; Yang, X.; Chao, S.; Leith, L.; Xiao, Z.; Mathur, A.; Chen, B. C.; Wu, D.-R.; Traeger, S. C.; McKinnon, M.; Barrish, J. C.; Robl, J. A.; Iwanowicz, E. J.; Suchard, S. J.; Dhar, T. G. M. J. Med. Chem. 2006, 49, 6946; (b) Potin, D.; Launay, M.; Nicolai, E.; Fabreguette, M.; Malabre, P.; Caussade, F.; Besse, B.; Skala, S.; Stetsko, D. K.; Todderud, G.; Beno, B. R.; Cheney, D. L.; Chang, C. J.; Sheriff, S.; Hollenbaugh, D. L.; Barrish, J. C.; Iwanowicz, E. J.; Suchard, S. J.; Dhar, T. G. M. Bioorg. Med. Chem. Lett. 2005, 15, 1161. 8. (a) Kelly, T. A.; Jeanfavre, D. D.; McNeil, D. W.; Woska, R. J.; Reilly, L. P.; Mainolfi, E. A.; Kishimoto, K. M.; Nabozny, G. H.; Zinter, R.; Bormann, B.; Rothlein, R. J. Immunol. 1999, 163, 5173≠5177; (b) Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.;

9.

10. 11. 12.

Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Nat. Med. 2001, 7, 687; (c) Sircar, I.; Furth, P.; Teegarden, B. R.; Morningstar, M.; Smith, N.; Griffith, R. WO 0130781 (to Tanabe Seiyaku), 2001; (d) Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza, R.; DeVries, P.; Leitza, S.; Reilly, E. B.; Okasinski, G. F.; Fesik, S. W.; von Geldern, T. W. J. Med. Chem. 2001, 44, 1202; (e) Gadek, T. R.; Burdick, D. J.; McDowell, R. S.; Stanley, M. S.; Marsters, J. C., Jr.; Paris, K. J.; Oare, D. A.; Reynolds, M. E.; Ladner, C.; Zioncheck, K. A.; Lee, W. P.; Gribling, P.; Dennis, M. S.; Skelton, N. J.; Tumas, D. B.; Clark, K. R.; Keating, S. M.; Beresini, M. H.; Tilley, J. W.; Presta, L. G.; Bodary, S. C. Science 2002, 295, 1086; (f) Wu, J.-P.; Emeigh, J.; Gao, A. A.; Goldberg, D. R.; Kuzmich, D.; Miao, C.; Potocki, I.; Qian, K. C.; Sorcek, R. J.; Jeanfavre, D. D.; Kishimoto, K.; Mainolfi, E. A.; Nabozny, G.; Peng, C.; Reilly, P.; Rothlein, R.; Sellati, R. H.; Woska, J. R.; Chen, S.; Gunn, J. A.; O'Brien, D.; Norris, S. H.; Kelly, T. A. J. Med. Chem. 2004, 47, 5356; (g) Wattanasin, S.; Kallen, J.; Myers, S.; Guo, Q.; Sabio, M.; Ehrhardt, C.; Albert, R.; Hommel, U.; Weckbecker, G.; Welzenbach, K.; Weitz-Schmidt, G. Bioorg. Med. Chem. Lett. 2005, 15, 1217. Last-Barney, K.; Davidson, W.; Cardozo, M.; Frye, L. L.; Grygon, C. A.; Hopkins, J. L.; Jeanfavre, D. D.; Pav, S.; Qian, C.; Stevenson, J. M.; Tong, L.; Zindell, R.; Kelly, T. A. J. Am. Chem. Soc. 2001, 123, 5643. PDB ID code 2O7N. DeLano, W.L. The PyMol Molecular graphics System. 2002. DeLano Scientific, San Carlos, CA, US. <http:/ www.pymol.org>. (a) Stephens, P. J.; Aamouche, A.; Devlin, F. J.; Superchi, S.; Donnoli, M. I.; Rosini, C. J. Org. Chem. 2001, 66, 2671; (b) Freedman, T. B.; Cao, X.; Phillips, L. M.; Cheng, P. T. W.; Dalterio, R.; Shu, Y.-Z.; Zhang, H.; Zhao, N.; Shukla, R. B.; Tymiak, A.; Gozo, S. K.; Nafie, L. A.; Gougoutas, J. Z. Chirality 2006, 18, 746.

